# Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

> **NCT02908217** · PHASE3 · COMPLETED · sponsor: **University Hospital, Brest** · enrollment: 113 (actual)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02908217
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-15
- **Primary completion:** 2020-11-12
- **Final completion:** 2020-11-12
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2020-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02908217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02908217, "Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02908217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*